Protein Kinase Inhibitors Drug Discovery

Drug Discovery Handbook

Volumn , Issue , 2005, Pages 1191-1257

  Parang, Keykavous ^a   Sun, Gongqin ^a  

^a UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

Abelson PTK (c Abl); Anticancer drug discovery; Protein kinase inhibitors (PKIs)

Indexed keywords

EID: 84889791431     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/0471728780.ch26     Document Type: Chapter

References (387)

1. Hunter, T. (1987). A thousand and one protein kinases. Cell, 50, 823-829.
2. Hunter, T. (2000). Signaling-2000 and beyond. Cell, 100, 113-127.
3. Manning, G.,Whyte, D. B., Martinez, R., Hunter, R., Sudarsanam, S. (2002). The protein kinase complement of the human genome. Science, 298, 1912.
4. Hubbard, S. R., Till, J. H. (2000). Protein tyrosine kinase structure and function. Annu. Rev. Biochem., 69, 373-398.
5. Ho, M., Bramson, H. N., Hansen,D. E., Knowles, J. R. Kaiser, E. T. (1988). Stereochemical course of the phospho group transfer catalyzed by cAMP-dependent protein-kinase. J. Am. Chem. Soc., 110, 2680-2681.
6. Aqvist, J., Kolmodin, K., Florian, J.,Warshel, A. (1999). Mechanistic alternatives in phosphate monoester hydrolysis:What conclusions can be drawn from available experimental data? Chem. Biol., 6, R71-R80.
7. Admiraal, S. J., Herschlag, D. (2000). The substrate-assisted general base catalysis model for phosphate monoester hydrolysis: Evaluation using reactivity comparisons. J. Am. Chem. Soc., 122, 2145-2148.
8. Mildvan, A. S. (1997). Mechanisms of signaling and related enzymes. Proteins, 29, 401-416.
9. Uckun, F. M., Mao, C. (2004). Tyrosine kinases as new molecular targets in treatment of inflammatory disorders and leukemia. Curr. Pharm. Des., 10, 1083-1091.
10. Williams, D. H., Mitchell, T. (2002). Latest developments in crystallography and structure-based design of protein kinase inhibitors as drug candidates. Curr.Opin. Pharmacol., 2, 1-7.
11. Scapin, G. (2002). Structural biology in drug design: Selective protein kinase inhibitors. Drug Discov. Today, 7, 601-611.
12. Hubbard, S. (2002). Protein tyrosine kinases:Autoregulation and small molecule inhibition. Curr. Opin. Struct. Biol., 12, 735-741.
13. Al-Obeidi, F. A.,Wu, J. J., Lam, K. S. (1998). Protein tyrosine kinases: Structure, substrate specificity, and drug discovery. Biopolymers, 47, 197-223.
14. Hubbard, S. R. (1999). Structural analysis of receptor tyrosine kinases. Prog. Biophys. Mol. Biol., 71, 343-358.
15. Munshi, S., Kornienko, M., Hall, D. L., Reid, J. C.,Waxman, L., Stirdivant, S. M., Darke, P. L., Kuo, L. C. (2002). Crystal structure of the Apo, unactivated insulinlike growth factor-1 receptor kinase. Implication for inhibitor specificity. J. Biol. Chem., 277, 38797-38802.
16. Xu,W., Harrison, S. C., Eck, M. J. (1997). Three-dimensional structure of the tyrosine kinase c-Src. Nature, 385, 595-602.
17. Xu,W., Doshi, A., Lei, M., Eck, M. J., Harrison, S. C. (1999). Crystal structures of c-Src reveal features of its autoinhibitory mechanism. Mol. Cell, 3, 629-638.
18. Mohammadi, M., Schlessinger, J., Hubbard, S. R. (1996). Structure of the FGF receptor tyrosine kinase domain reveals a novel autoinhibitory mechanism. Cell, 86, 577-587.
19. Mohammadi, M., McMahon, G., Sun, L., Tang, C., Hirth, P., Yeh, B. K., Hubbard, S. R., Schlessinger, J. (1997). Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science, 276, 955-960.
20. McTigue, M. A., Wickersham, J. A, Pinko, C., Showalter, R. E., Parast, C. V., Tempczyk-Russell, A., Gehring, M. R., Mroczkowski, B., Kan, C. C., Villafranca, J. E., Appelt, K. (1999). Crystal structure of the kinase domain of human vascular endothelial growth factor receptor 2: A key enzyme in angiogenesis. Structure with Folding & Design, 7, 319-330.
21. Zhu, X., Kim, J. L., Newcomb, J. R., Rose, P. E., Stover,D. R.,Toledo, L. M., Zhao, H., Morgenstem, K. A. (1999). Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors. Structure with Folding & Design, 7, 651-661.
22. Yamaguchi, H., Hendrickson, W. A. (1996). Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation. Nature, 384, 484-489.
23. Sicheri, F., Moarefi, I., Kuriyan, J. (1997). Crystal structure of the Src family tyrosine kinase Hck. Nature, 385, 602-609.
24. Schindler,T., Sicheri, F., Pico, A., Gazit, A., Levitzki, A.,Kuriyan, J. (1999). Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor. Mol. Cell, 3, 639-648.
25. Mao, C., Zhou, M., Uckun, F. M. (2001). Crystal structure of Bruton's tyrosine kinase domain suggests a novel pathway for activation and provides insights into the molecular basis of X-linked agammaglobulinemia. J. Biol. Chem., 276, 41435-41443.
26. Schindler, T., Bornmann,W., Pellicena, P., Miller,W. T., Clarkson, B., Kuriyan, J. (2000). Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science, 289, 1938-1942.
27. Taylor, S. S., Radzio-Andzelm, E. (1994). Three protein kinase structures define a common motif. Structure, 2, 345-355.
28. Stout, T. J., Foster, P. G., Matthews, D. J. (2004). High-throughput structural biology in drug discovery: Protein kinases. Curr. Pharm. Des., 10, 1069-1082.
29. Sawyer, T. K. (1998). Src homology-2 domains: Structure, mechanisms, and drug discovery. Biopolymers, 47, 243-261.
30. Sicheri, F.,Kuriyan, J. (1997). Structures of Src-family tyrosine kinases. Curr.Opin. Struct. Biol., 7, 777-785.
31. Songyang, Z., Shoelson, S. E., Chaudhuri, M., Gish, G., Pawson, T., Haser,W. G., King, F., Roberts, T., Ratnofsky, S., Lechleider, R. J., Neel, B. G., Birge, R. B., Fajardo, J. E., Chou, M. M., Hanatusa, H., Schaffhausen, B., Cantley, L. C. (1993). SH2 domains recognize specific phosphopeptide sequences. Cell, 72, 767-778.
32. Sadowski, I., Stone, J. C., Pawson, T. (1986). A noncatalytic domain conserved among cytoplasmic protein-tyrosine kinases modifies the kinase function and transforming activity of Fujinami sarcoma virus P130gag-fps. Mol. Cell. Biol., 6, 4396-4408.
33. Cantley, L. C., Auger, K. R., Carpenter, C., Duckworth, B., Graziana, A., Kapeller, R., Soltoff, S. (1991). Oncogenes and signal transduction. Cell, 64, 281-302.
34. Fukui, Y., Hanafusa, H. (1991). Requirement of phosphatidylinositol-3 kinase modification for its association with p60src. Mol. Cell. Biol., 11, 1972-1979.
35. Schaller, M. D., Hilderbrand, J. D., Shannon J. D., Fox, J.W.,Vines, R. R., Parsons, J. T. (1994).Autophosphorylation of the focal adhesion kinase, pp125FAK, directs SH2 dependent binding of pp60src. Mol. Cell. Biol., 14, 1680-1688.
36. Taylor, S. J., Shalloway, D. (1994). An RNA-binding protein associated with Src through its SH2 and SH3 domains in mitosis. Nature, 368, 867-871.
37. Petch, L. A., Bockholt, S. M., Bouton, A., Parsons, J. T., Burridge, K. (1995). Adhesion-induced tyrosine phosphorylation of the p130 src substrate. J. Cell. Sci., 108, 1371-1379.
38. Johnson, L. N., Noble, M. E., Owen, D. J. (1996). Active and inactive protein kinases: Structural basis for regulation. Cell, 85, 149-158.
39. Adams, J. A. (2003). Activation loop phosphorylation and catalysis in protein kinases: Is there functional evidence for the autoinhibitor model? Biochemistry, 42, 601-607.
40. Toker, A. N., Newton, A. C. (2000). Cellular signaling: Pivoting around PDK1. Cell, 103, 185-188.
41. Till, J. H., Ablooglu, A. J., Frankel, M., Bishop, S. M., Kohanski, R. A., Hubbard, S. R. (2001). Crystallographic and solution studies of an activation loop mutant of the insulin receptor tyrosine kinase: Insights into kinase mechanism. J. Biol. Chem., 276, 10049-10055.
42. Ablooglu, A. J., Frankel, M., Rusinova, E., Ross, J. B. A., Kohanski, R. A. (2001). Multiple activation loop conformations and their regulatory properties in the insulin receptor's kinase domain. J. Biol. Chem., 276, 46933-46940.
43. Orr, J.W., Newton, A. C. (1994). Requirement for negative charge on "activation loop" of protein kinase C. J. Biol. Chem., 269, 27715-27718.
44. Wybenga-Groot, L. E., Baskin, B., Ong, S. H., Tong, J., Pawson, T., Sicheri, F. (2001). Structural basis for autoinhibition of the Ephb2 receptor tyrosine kinase by the unphosphorylated juxtamembrane region. Cell, 106, 745-757.
45. Moarefi, H., LaFevre-Bernt, M., Sicheri, F., Huse, M., Lee, C.-H., Kuriyan, J., Miller, W. T. (1997). Activation of the Src-family tyrosine kinase Hck by SH3 domain displacement. Nature, 385, 650-653.
46. Mandine, E., Jean-Baptiste, V., Vayssiere, B., Gofflo, D., Benard, D., Sarubbi, E., Deprez, P., Baron, R., Superti-Furga,G., Lesuisse,D. (2002). High-affinity Src-SH2 ligands which do not activate Tyr(527)-phosphorylated Src in an experimental in vivo system. Biochem. Biophys. Res. Commun., 298, 185-192.
47. Liu, X., Brodeur, S. R., Gish, G., Songyang, Z., Cantley, L. C., Laudano, A. P., Pawson, T. (1993). Regulation of c-Src tyrosine kinase activity by the Src SH2 domain. Oncogene, 8, 1119-1126.
48. Alonso, G., Koegl, M., Mazurenko, N., Courtneidge, S. A. (1995). Sequence requirements for binding of Src family tyrosine kinases to activated growth factors. J. Biol. Chem., 270, 9840-9848.
49. Boerner,R. J., Kassel,D. B., Barker, S. C., Ellis,B., DeLacy, P., Knight,W. B. (1996). Correlation of the phosphorylation states of pp60c-src with tyrosine kinase activity: The intramolecular pY530-SH2 complex retains significant activity if Y419 is phosphorylated. Biochemistry, 35, 9519-9525.
50. Erpel, T., Courtneidge, S. A. (1995). Src family protein tyrosine kinases and cellular signal transduction pathways. Curr. Opin. Cell Biol., 7, 176-182.
51. Thomas, J.W., Ellis, B., Boerner, R. J., Knight,W. B.,Wite, G. C., II, Shaller, M. D. (1998). SH2-and SH3-mediated interactions between focal adhesion kinase and Src. J. Biol. Chem., 273, 577-583.
52. Alexandropoulos, K., Baltimore,D. (1996). Coordinate activation of c-Src by SH3-and SH2 binding sites on a novel, p130CAS-related protein, Sin. Genes Devel., 10, 1341-1355.
53. Profit,A. A., Lee,T. R., Niu, J., Lawrence,D. S. (2001). Molecular rulers:An assessment of distance and spatial relationships of Src tyrosine kinase SH2 and active site regions. J. Biol. Chem., 276, 9446-9451.
54. Biscardi, J. S.,Tice,D. A., Parsons, S. J. (1999). c-Src, receptor tyrosine kinases, and human cancer. Adv. Cancer Res., 76, 61-119.
55. Jiang, G., Zhang, B. B. (2002). PI3-kinase and its up-and down-stream modulators as potential targets for the treatment of type II diabetes. Front. Biosci., 7, 903-907.
56. Frame, S., Cohen, P. (2001). GSK3 takes centre stage more than 20 years after its discovery. Biochem. J., 359(Pt. 1), 1-16.
57. Vlahos, C. J., McDowell, S. A., Clerk, A. (2003). Kinases as therapeutic targets for heart failure. Nat. Rev. Drug Discov., 2, 99-113.
58. Mucke, H. A. (2003). CEP-1347 (Cephalon). IDrugs, 6, 377-383.
59. Lee, J. C., Kumar, S., Griswold, D. E., Underwood, D. C.,Votta, B. J., Adams, J. L. (2000). Inhibition of p38 MAP kinase as a therapeutic strategy. Immunopharmacology, 47, 185-201.
60. Traxler, P. (2003). Tyrosine kinases as targets in cancer therapy-Successes and failures. Expert Opin. Ther. Patents, 7, 215-234.
61. Gray, N., Detivaud, L., Doerig, C., Meijer, L. (1999). ATP-site directed inhibitors of cyclin-dependent kinases. Curr. Med. Chem., 6, 859-875.
62. Collett, M. S., Erikson, R. L. (1978). Protein kinase activity associated with the avian sarcoma virus src gene product. Proc. Natl. Acad. Sci. USA, 75, 2021-2024.
63. Klint, P., Claesson-Welsh, L. (1999). Signal transduction by fibroblast growth factor receptors. Front. Biosci., 4, D165-D177.
64. Dominguez, M.,Wasserman, J. D., Freeman, M. (1998). Multiple functions of the EGF receptor in Drosophila eye development. Curr. Biol., 8, 1039-1048.
65. Sieg, D. J., Hauck, C. R., Ilic, D., Klingbeil, C. K., Schaefer, E., Damsky, C. H., Schlaepfer, D. D. (2000). FAK integrates growth-factor and integrin signals to promote cell migration. Nat. Cell Biol., 2, 249-256.
66. Casaccia-Bonnefil, P., Gu, C., Chao, M. V. (1999). Neurotrophins in cell survival/ death decisions. The functional roles of glial cells in health and disease. Adv. Exper. Med. Biol., 468, 275-282.
67. Van der Geer, P., Hunter, T., Lindberg, R. A. (1994). Receptor protein-tyrosine kinases and their signal transduction pathways. Annu. Rev.Cell. Biol., 10, 251-337.
68. Carpenter, G., Cohen, S. (1979). Epidermal growth factor. Annu. Rev. Biochem., 48, 193-216.
69. Carpenter, G. (1987). Receptors for epidermal growth factor and other polypeptide mitogens. Annu. Rev. Biochem., 56, 881-914.
70. Quirion, R., Araujo, D., Nair, N. P., Chabot, J. G. (1988). Visualization of growth factor receptor sites in rat forebrain. Synapse, 2, 212-218.
71. Klapper, L. N., Kirschbaum, M. H., Sela, M., Yarden, Y. (2000). Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv. Cancer Res., 77, 25-79.
72. Olayioye, M. A., Neve, R. M., Lane, H. A., Hynes, N. E. (2000). The ErbB signaling network: Receptor heterodimerization in development and cancer. EMBO J., 19, 3159-3167.
73. Sporn, M. B., Roberts, A. B. (1985). Autocrine growth factors and cancer, Nature, 313, 745-747.
74. Salomon,D. S., Brandt, R., Ciardiello, F., Normanno,N. (1995). Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol., 19, 183-232.
75. Strawn, L. M., McMahon, G., App, H., Schreck, R., Kuchler,W. R., Longhi, M. P., Hui, T. H., Tang, C., Levitzki, A., Gazit, A., Chen, I., Keri, G., Orfi, L., Risau,W., Flamme, I., Ullrich, A., Hirth, K. P., Shawver, L. K. (1996). Flk-1 as a target for tumor growth inhibition. Cancer Res., 56, 3540-3545.
76. Verheul, H. M., Jorna, A. S., Hoekman, K., Broxterman, H. J., Gebbink, M. F., Pinedo, H. M. (2000). Vascular endothelial growth factor-stimulated endothelial cells promote adhesion and activation of platelets. Blood, 96, 4216-4221.
77. Matsuzaki, K., Yoshitake, Y., Matuo, Y., Sasaki, H., Nishikawa, K. (1989). Monocolonal antibodies against heparin-binding growth factor II/basic fibroblast growth factor that block its biological activity: Invalidity of the antibodies for tumor angiogenesis. Proc. Natl. Acad. Sci. USA, 86, 9911-9915.
78. Dennis, P. A., Rifkin, D. B. (1990). Studies on the role of basic fibroblast growth factor in vivo: Inability of neutralizing antibodies to block tumor growth. J. Cell Physiol., 144, 84-98.
79. Ferrara, N., Hillan, K. J., Gerber, H.-P., Novotony,W. (2004). Discover and development of Bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Dis., 3, 391-400.
80. Abu-Duhier, F. M., Goodeve, A. C.,Wilson,G. A., Care, R. S., Peake, I. R., Reilly, J.T. (2001). Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia. Br. J. Haematol., 113, 983-988.
81. Laird, A. D., Christensen, J. G., Li, G., Carver, J., Smith, K., Xin, X., Moss, K. G., Louie, S. G., Mendel,D. B., Cherrington, J. M. (2002). SU6668 inhibits Flk-1/KDR and PDGFRbeta in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice. FASEB J., 16, 681-690.
82. Mauro, M. J., Druker, B. J. (2001). STI571: Targeting BCR-ABL as therapy for CML. Oncologists, 6, 233-238.
83. Sawyers,C. L. (1999). Chronic myeloid leukemia. N. Engl. J. Med., 340, 1330-1340.
84. Warmuth, M., Damoiseaux, R., Liu, Y., Fabbro, D., Gray, N. (2003). Src family kinases: Potential targets for the treatment of human cancer and leukemia. Curr. Pharm. Des., 9, 2043-2059.
85. Susa, M., Teti, A. (2000). Tyrosine kinase Src inhibitors: Potential therapeutic application. Drugs News Perspect., 13, 169-175.
86. Weber, T. K., Steele, G., Summerhayes, I. C. (1992). Differential pp60c-src activity in well and poorly differentiated human colon carcinomas and cell lines. J. Clin. Invest., 90, 815-821.
87. Ottenholf-Kalff, A. E., Rijksen, G., van Beurden, E. A., Hennipman, A., Michels, A. A., Staal,G. E. (1992). Characterization of protein tyrosine kinase from human breast cancer. Cancer Res., 49, 4773-4778.
88. Avizienyte, E.,Wyke,A.W., Jones,R. J., McLean,G.W.,Westhoff, M. A., Brunton, V. G., Frame, M. C. (2002). Src-induced de-regulation of E-cadherin in colon cancer cells requires integrin signaling. Nat. Cell Biol., 4, 632-638.
89. Thomas, S. M., Brugge, J. S. (1997). Cellular functions regulated by Src family kinases. Annu. Rev. Cell Devel. Biol., 13, 513-609.
90. Shakespeare,W. C., Metcalfe, C. A. 3rd,Wang, Y., Sundaramoorthi, R., Keenan, T.,Weigele, M., Bohacek, R. S., Delgarne,D. C., Sawyer,T. K. (2003). Novel bonetargeted Src tyrosine kinase inhibitor drug discovery. Curr. Clin. Drug. Discov. Devel., 6, 729-741.
91. Lowe, C., Yoneda, T., Boyce, B. F., Chen, H., Mundy, G. R., Soriano, P. (1993). Osteopetrosis in Src-deficient mice is due to an autonomous defect of osteoclasts. Proc. Natt. Acad. Sci. USA, 90, 4485-4489.
92. Boyce, B. F.,Yoneda, T., Lowe, C., Soriano, P., Mundy, G. R. (1992). Requirement of pp60c-Src expression for osteoclasts to form ruffled borders and resorb bone in mice. J. Clin. Invest., 90, 1622-1627.
93. Soriano, P., Montgomery, C., Geske, R., Bradley, A. (1991). Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell, 64, 693-702.
94. Marzia, M., Sims, N. A., Voit, S., Migliaccio, S., Taranta, A., Bernardini, S., Faraggiana, T., Yoneda, T., Mundy, G. R., Boyce, B. F., Baron R., Teti. A. (2000). J. Cell Biol., 151, 311-320.
95. Kousteni, S., Bellido, T., Plotkin, L. I., O'Brien, C. A., Bodenner, D. L., Han, L., Han, K., DiGregorio, G. B., Katzenellenbogen, J. A., Katzenellenbogen, B. S., Roberson, P. K., Weinstein, R. S., Jilka, R. L., Manolagas, S. C. (2001). Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: Dissociation from transcriptional activity. Cell, 104, 719-730.
96. Abu-Amer,Y., Ross, F. P., Schlesinger, P.,Tondravi, M. M.,Teitelbaum, S. L. (1997). Substrate recognition by osteoclast precursors induces C-src/microtubule association. J. Cell Biol., 137, 247-258.
97. Wong, B. R., Besser, D., Kim, N., Arron, J. R., Vologodskaia, M., Hanafusa, H., Choi, Y. (1999). TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. Mol. Cell, 4, 1041-1049.
98. Tanaka, S., Amling, M., Neff, L., Peyman, A., Uhlmann, E., Levy J. B., Baron, R. (1996). c-Cbl is downstream of c-Src in a signalling pathway necessary for bone resorption. Nature, 383, 528-531.
99. Jeschke, M., Brandi, M.-L., Susa, M. (1998). Expression of Src family kinases and their putative substrates in the human preosteoclastic cell line FLG 29.1. J. Bone Miner. Res., 13, 1880-1889.
100. Lowell, C. A., Berton, G. (1999). Integrin signal transduction in myeloid leukocytes. J. Leukoc. Biol., 65, 313-320.
101. Missbach, M., Jeschke, M., Feyen, J., Muller, K., Glatt, M., Green, J., Susa, M. (1999). A novel inhibitor of the tyrosine kinase Src suppresses phosphorylation of its major cellular substrates and reduces bone resorption in vitro and in rodent models in vivo. Bone, 24, 437-449.
102. Shakespeare, W., Yang, M., Bohacek, R., Cerasoli, F., Stebbins, K., Sundaramoorthi, R., Azimioara, M., Vu, C., Pradeepan, S., Metcalf, C., Haraldson, C., Merry, T., Dalgarno, D., Narula, S., Hatada, M., Lu, X., van Schravendijk, M. R., Adams, S., Violette, S., Smith, J., Guan, W., Bartlett, C., Herson, J., Iuliucci, J., Weigele, M., Sawyer, T. (2000). Structure-based design of an osteoclast-selective, nonpeptide src homology 2 inhibitor with in vivo antiresorptive activity. Proc. Natl. Acad. Sci. USA, 97, 9373-9378.
103. Luttrell,D. K., Lee,A., Lansing,T. J., Crosby,R. M., Jung,K.D.,Willard,D., Luther, M., Rodriguez, M., Berman, J., Gilmer, T. M. (1994). Involvement of pp60c-src with two major signaling pathways in human breast cancer. Proc. Natl. Acad. Sci. USA, 91, 83-87.
104. Frame, M. (2002). C-Src in cancer: Deregulation and consequences for cell behavior. Biochim. Biophys. Acta, 1602, 114-130.
105. Kyriakis, J. M., Avruch, J. (2001). Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol. Rev., 81, 807-869.
106. Pombo, C. P., Bonventre, J. V.,Avruch, J.,Woodgett, J. R., Kyriakis, J. M., Force,T. (1994). The stress-activated protein kinases (SAPKs) are major c-Jun aminoterminal kinases activated by ischemia and reperfusion. J. Biol. Chem., 269, 26546-26551.
107. Pearson, G., Robinson, F., Beers, G. T., Xu, B. E., Karandikar, M., Berman, K., Cobb, M. H. (2001). Mitogen-activated protein (MAP) kinase pathways: Regulation and physiological functions. Endocr. Rev., 22, 153-183.
108. Cobb, M. H., Goldsmith, E. J. (1995). How MAP kinases are regulated. J. Biol. Chem., 270, 14843-14864.
109. Minden, A., Karin, M. (1997). Regulation and function of the JNK subgroup of MAP kinases. Biochem. Biophys. Acta, 1333, F85-F104.
110. Hunter, T. (1995).When is a lipid kinase not a lipid kinase? When it is a protein kinase. Cell, 80, 225-236.
111. Chen, Z., Gibson,T. B., Robinson, F., Silvestro, L., Pearson, G., Xu, B., Wright, A., Vanderbilt, C., Cobb, M. H. (2001). MAP kinases. Chem. Rev., 101, 2449-2476.
112. Marshall, C. J. (1995). Specificity of receptor tyrosine kinase signaling: Transient versus sustained extracellular signal-regulated kinase activation. Cell, 80, 179-185.
113. Marshall, C. J. (1994). MAP kinase kinase kinase, MAP kinase kinase and MAP kinase. Curr. Opin. Genet. Devel., 4, 82-89.
114. Sugden, P. H., Clerk, A. (1997). Regulation of the ERK subgroup of MAP kinase cascades through G protein-coupled receptors. Cell Signal, 9, 337-351.
115. Cobb, M. H., Boulton, T.G., Robbins, D. J. (1991). Extracellular signal-regulated kinases: ERKs in progress. Cell Regul., 2, 965-978.
116. Ono, K., Han, J. (2000). The p38 signal transduction pathway: Activation and function. Cell Signal, 12, 1-13.
117. Mazzucchelli, C., Brambilla, R. (2000). Ras-related and MAPK signalling in neuronal plasticity and memory formation. Cell Mol. Life Sci., 57, 604-611.
118. Harper, J. W., Adams, P. D. (2001). Cyclin-dependent kinases. Chem. Rev., 101, 2511-2526.
119. Bramson, H. N., Corona, J., Davis, S. T., Dickerson, S. H., Edelstein, M., Frye, S. V., Gampe, R. T. Jr., Harris, P. A., Hassell, A., Holmes, W. D., Hunter, R. N., Lackey, K. E., Lovejoy, B., Luzzio, M. J., Montana, V., Rocque,W. J., Rusnak, D., Shewchuk, L., Veal, J. M., Walker, D. H., Kuyper, L. F. (2002). Oxindole-based inhibitors of cyclin-dependent kinase 2 (CDK2): Design, synthesis, enzymatic activities, and X-ray crystallographic analysis. J. Med. Chem., 44, 4339-4358.
120. Sherr, C. J. (1996). Cancer cell cycles. Science, 274, 1672-1677.
121. Frizelle, S. P., Grim, J., Zhou, J., Gupta, P., Curiel, D. T., Geradts, J., Kratzke, R. A. (1998). Re-expression of p16INK4a in mesothelioma cells results in cell cycle arrest, cell death, tumor suppression and tumor regression. Oncogene, 16, 3087-3095.
122. Barnes,D. M., Gillet, C. E. (1998). Cyclin D1 in breast cancer. Breast Cancer Res. Treat., 52, 1-15.
123. Roussel. M. F. (1999). The INK4 family of cell cycle inhibitors in cancer. Oncogene, 18, 5311-5317.
124. Nevins, J. R. (2001). The Rb/E2F pathway and cancer. Hum. Mol. Genet., 10, 699-703.
125. Tsao, H., Benoit, E., Sober,A. J.,Thiele, C., Haluska, F.G. (1998). Novel mutations in the p16/CDKN2A binding region of the cyclin-dependent kinase-4 gene. Cancer Res., 58, 109-113.
126. Goekjian, P. G., Jirousek, M. R. (1999). Protein kinase C in the treatment of disease: Signal transduction pathways, inhibitors, and agents in development. Curr. Med. Chem., 6, 877-903.
127. Dekker, L. V., Parker, P. (1994). Protein kinase C-A question of specificity. Trends Biochem. Sci., 19, 73-77.
128. Tanaka, C., Saito, N. (1992). Localization of subspecies of protein kinase C in the mammalian central nervous system. Neurochem. Int., 21, 499-512.
129. Blobe, G. C., Obeid, L. M., Hannun,Y. A. (1994). Regulation of protein kinase C and role in cancer biology. Cancer Metastasis Rev., 13, 724-730.
130. Ron, D., Kazanietz, M. G. (1999). New insights into the regulation of protein kinase C and novel phorbol esters. FASEB J., 27, 1658-1676.
131. Bullock, W. H., Magnuson, S. R., Choi, S., Gunn, D. E., Rudolph. J. (2002). Prospects for kinase activity modulators in the treatment of diabetes and diabetic complications. Curr. Top. Med. Chem., 2, 915-938.
132. Way, K. J., Katai, N., King, G. L. (2001). Protein kinase C and the development of diabetic vascular complications. Diabetes Med., 18, 945-959.
133. Takenaga, K., Takahashi, K. (1996). Effects of 12-O-tetradecanoylphorbol-13-acetate on adhesiveness and lung-colonising ability of Lewis lung carcinoma cells. Cancer Res., 46, 375-380.
134. Schwartz, G. K., Juang, K., Kelsen, D., Albino, A. P. (1993). Protein kinase C: A novel target for inhibiting gastric cancer cell invasion. J. Natl. Cancer Inst., 85, 402-407.
135. O'Brian, C. A.,Vogel,V. G., Singletary, S. E.,Ward, N. E. (1989). Elevated protein kinase C expression in human breast tumour biopsies relative to normal breast tissue. Cancer Res., 49, 3215-3217.
136. Gokmen-Polar,Y., Murray,N.,Velasco, M. A., Gatlica, Z., Fields,A. P. (2001). Elevated protein kinase C bII is an early promotive event in colon carcinogenesis. Cancer Res., 61, 1375-1381.
137. Robinson-White, A., Stratakis, C. (2002). Protein kinase A signaling: "Cross-talk" with other pathways in endocrine cells. Ann. NY Acad. Sci., 968, 256-270.
138. Rajnicek, A., Britland, S., McCaig, C. (1997). Contact guidance of CNS neurites on grooved quartz: Influence of groove dimensions, neuronal age and cell type. J. Cell. Sci., 110, 2905-2913.
139. Rajnicek, A., McCaig, C. (1997). Guidance of CNS growth cones by substratum grooves and ridges: Effects of inhibitors of the cytoskeleton, calcium channels and signal transduction pathways. J. Cell. Sci., 110, 2915-2924.
140. Hu, E., Lee, D. (2003). Rho kinase inhibitors as potential therapeutic agents for cardiovascular diseases. Curr. Opin. Investig. Drugs, 4, 1065-1075.
141. Riento, K., Ridley A. J. (2003). Rocks: Multifunctional kinases in cell behaviour. Nat. Rev. Mol. Cell Biol., 4, 446-456.
142. Katso, R., Okkenhaug, K., Ahmadi, K., White, S., Timms, J., Waterfield, M. D. (2001). Cellular function of phosphoinositide 3-kinases: Implications for development, homeostasis, and cancer. Annu. Rev. Cell Devel. Biol., 17, 615-675.
143. McKenna, W. G., Muschel, R. J. (2003). Targeting tumor cells by enhancing radiation sensitivity. Genes Chromosomes Cancer, 38, 330-338.
144. Woodgett, J. R. (1990). Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J., 9, 2431-2438.
145. Kim, H.-S., Skurk, C.,Thomas, S. R., Bialik, A., Suhara,T., Kureishi,Y., Birnbaum, M.,Keaney, J. F. Jr.,Walsh. K. (2002). Regulation of angiogenesis by glycogen synthase kinase-3beta. J. Biol. Chem., 277, 41888-41896.
146. Kaidanovich, O., Eldar-Finkelman, H. (2002). The role of glycogen synthase kinase-3 in insulin resistance and Type 2 diabetes. Exp. Opin. Ther. Targets, 6, 555-561.
147. Eldar-Finkelman, H. (2002). Glycogen synthase kinase 3: An emerging therapeutic target. Trends Mol. Med., 8, 126-132.
148. Wagman, A. S., Johnson, K. W., Bussiere, D. E. (2004). Discovery and development of GSK3 inhibitors for the treatment of type 2 diabetes. Curr. Pharm. Des., 10, 1105-1137.
149. Laird, A. D., Cherrington, J. M. (2003). Small molecule tyrosine kinase inhibitors: Clinical development of anticancer agents. Expert Opin. Investig. Drugs, 12, 51-64.
150. Cohen, P. (2002). Protein kinases-The major drug targets of the twenty-first century? Nat. Rev. Drug Discov., 1, 309-315.
151. Druker, B. J. (2003). Imatinib alone and in combination for chronic myeloid leukemia. Semin. Hematol., 40, 50-58.
152. Wakeling, A. E. (2002). Epidermal growth factor receptor tyrosine kinase inhibitors. Curr. Opin. Pharmacol., 2, 382-387.
153. Marx, S.O., Marks,A. R. (2001). Bench to bedside:The development of rapamycin and its application to stent restenosis. Circulation, 104, 852-855.
154. Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., Baselga, J., Norton, L. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med., 344, 783-792.
155. Mitchell, P. (2004). Erbitux diagnostic latest adjunct to cancer therapy. Nat. Biotechnol., 22, 363-364.
156. Roskoski, R. Jr. (2004). The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem. Biophys. Res. Commun., 319, 1-11.
157. Fabbro, D., Ruetz, S., Buchdunger, E., Cowan-Jacob, S. W., Fendrich, G., Liebetanz, J., Mestan, J., O'Reilly, T., Traxler, P., Chaudhuri, B., Fretz, H., Zimmermann, J., Meyer, T., Giorgio, C., Furet, G., Manley, P. W. (2002). Protein kinases as targets for anticancer agents: From inhibitors to useful drugs. Pharmacol. Ther., 93, 79-98.
158. Levitzki, A. (2003). Protein kinase inhibitors as a therapeutic modality. Acc. Chem. Res., 36, 462-469.
159. Force,T., Kuida, K., Namchuk, M., Parang, K., Kyriakis, J. M. (2004). Inhibitors of protein kinase signaling pathways. Circulation, 109, 1196-1205.
160. Toledo, L. M., Lydon, N. B., Elbaum, D. (1999). The structure-based design of ATP-site directed protein kinase inhibitors. Curr. Med. Chem., 6, 775-805.
161. Traxler, P. (1998). Tyrosine kinase inhibitors in cancer treatment (part II). Expert Opin. Ther. Patents, 8, 1599-1625.
162. Bridges, A. J. (2001). Chemical inhibitors of protein kinases. Chem. Rev., 101, 2541-2571.
163. Myers, M. R., He,W., Hulme, C. (1997). Inhibitors of tyrosine kinases involved in inflammation and autoimmune disease. Curr. Pharm. Des., 3, 473-502.
164. Dancey, J., Sausville, E. A. (2003). Issues and progress with protein kinase inhibitors for cancer treatment. Nat. Drug Discov., 2, 296-313.
165. Nam,N. H., Parang,K. (2003). Current targets for anticancer drug discovery. Curr. Drug Targets, 4, 159-179.
166. Sawyer, T., Boyce, B., Dalgarno, D., Luliucci, J. (2001). Src inhibitors: Genomics to therapeutics. Expert Opin. Investig. Drugs, 10, 1327-1344.
167. Orchard, S. (2002). Kinases as targets: Prospects for chronic therapy. Curr. Opin. Drug Discov. Devel., 5, 713-717.
168. Garcia-Echeverria, C., Traxler, P., Evans, D. B. (2000). ATP site-directed competitive and irreversible inhibitors of protein kinases. Med. Res. Rev., 20, 28-57.
169. Fischer, P. M. (2004). The design of drug candidate molecules as selective inhibitors of therapeutically relevant protein kinases. Curr. Med. Chem., 11, 1563-1583.
170. Fischer, O. M., Streit, S., Hart, S., Ullrich, A. (2003). Beyond Herceptin and Gleevec. Curr. Opin. Chem. Biol., 7, 490-495.
171. Sawyer, T. K. (2004). Cancer metastatis therapeutic targets and drug discovery: Emerging small-molecule protein kinase inhibitors. Expert Opin. Invest. Drugs, 13, 1-19.
172. Wu, S.Y.,McNae, I.,Kontopidis,G., McClue, S. J., McInnes,C., Stewart, K. J.,Wang, S., Zheleva, D. I., Marriage, H., Lane, D. P., Taylor, P., Fischer, P. M.,Walkinshaw, M. D. (2003). Discovery of a novel family of CDK inhibitors with the program LIDAEUS: Structural basis for ligand-induced disordering of the activation loop. Structure (Camb)., 11, 399-410.
173. Rossé, G., Séquin, U., Mett, H., Furet, P., Traxler, P., Fretz, H. (1997). Synthesis of modified tripeptides and tetrapeptides as potential bisubstrate inhibitors of the epidermal growth factor receptor protein tyrosine kinase. Helv. Chim. Acta, 80, 653-670.
174. Yuan, C. J., Jakes, S., Elliot, S., Graves, D. (1990). A rationale for the design of an inhibitor of tyrosine kinase. J. Biol. Chem., 265, 16205-16209.
175. Cushman, M., Chinnasamy, P., Chakraborti, A. K., Jurayj, J., Geahlen, R. L., Haugwitz, R. D. (1990). Synthesis of [beta-(4-pyridyl-1-oxide)-l-alanine4]-angiotensin I as a potential suicide substrate for protein-tyrosine kinases. Int. J. Pept. Protein Res., 36, 538-543.
176. Bohmer, F. D., Kaagyozov, L., Uecker, A., Serve, H., Botzki, A., Mahboobi, S., Dove, S. (2003). A single amino acid exchange inverts susceptibility of related receptor tyrosine kinases for the ATP-site inhibitor STI-571. J. Biol. Chem., 14, 5148-5155.
177. Huse, M.,Kuriyan, J. (2002).The conformational plasticity of protein kinases. Cell, 109, 275-282.
178. Davies, S. P., Reddy, H., Caivano, M., Cohen, P. (2000). Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J., 351, 95-105.
179. Bain, J., McLauchlan, H., Elliott, M., Cohen, P. (2003). The specificities of protein kinase inhibitors: An update. Biochem. J., 371, 199-204.
180. Lawrence, D. S., Niu, J. (1998). Protein kinase inhibitors: The tyrosine-specific protein kinases. Pharmacol. Ther., 77, 81-114.
181. Topaly, J., Zeller,W. J., Fruehauf, S. (2001). Synergistic activity of the new ABLspecific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCRABL-positive chronic myelogenous leukemia cells. Leukemia, 15, 342-347.
182. Thiesing, J. T., Ohno-Jones, S., Kolibaba, K. S., Druker, B. J. (2000). Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. Blood, 96, 3195-3199.
183. Bogoyevitch, M. A., Boehm, I., Oakley, A., Ketterman, A. J., Barr, R. K. (2004). Targeting the JNK MAPK cascade for inhibition: Basic science and therapeutic potential. Biochim. Biophys. Acta, 1697, 89-101.
184. Shen, G. X. (2003). Selective protein kinase C inhibitors and their applications. Curr. Drug Targets Cardiovasc. Haematol. Disord., 3, 301-307.
185. Kim, H., Sasaki,T., Maeda, K.,Koya,D., Kashiwagi, A.,Yasuda,H. (2003). Protein kinase Cbeta selective inhibitor LY333531 attenuates diabetic hyperalgesia through ameliorating cGMP level of dorsal root ganglion neurons. Diabetes, 52, 2102-2109.
186. Showalter, H. D., Kraker, A. J. (1997). Small molecule inhibitors of the plateletderived growth factor receptor, the fibroblast growth factor receptor, and Src family tyrosine kinases. Pharmacol. Ther., 76, 55-71.
187. Druker, B. J., Lydon, N. B. (2000). Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J. Clin. Invest., 105, 3-7.
188. Graziani, Y., Erikson, E., Erikson, R. L. (1983). The effect of quercetin on the phosphorylation activity of the Rous sarcoma virus transforming gene product in vitro and in vivo. Eur. J. Biochem., 135, 583-589.
189. Hagiwara, M., Inoue, S., Tanaka, T., Nunoki, K., Ito, M., Hidaka, H. (1988). Differential effects of flavonoids as inhibitors of tyrosine protein kinases and serine/threonine protein kinases. Biochem. Pharmacol., 37, 2987-2992.
190. Fischer, P. M., Lane, D. P. (2000). Inhibitors of cyclin-dependent kinases as anticancer therapeutics. Curr. Med. Chem., 7, 1213-1245.
191. Sedlacek, H. H. (2001). Mechanisms of action of flavopiridol. Crit. Rev. Oncol. Hematol., 38, 139-170.
192. Akiyama,T., Ishida, J., Nakagawa, S., Ogawara, H.,Watanabe, S. I., Itoh,N., Shibuy, M., Fukami, Y. (1987). Genistein, a specific inhibitor of tyrosine-specific protein kinases. J. Biol. Chem., 262, 5592-5595.
193. Nishio, K., Miura, K., Ohira, T., Heiko, Y., Saijo, N. (1994). Genistein, a tyrosine kinase inhibitor, decreased the affinity of p56lck to beta-chain of interleukin-2 receptor in human natural killer (NK)-rich cells and decreased NK-mediated cytotoxicity. Proc. Soc. Exp. Biol. Med., 207, 227-233.
194. Dudley, D. T., Pang, L., Decker, S. J., Bridges, A. J., Saltiel, A. R. (1995). A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc. Natl. Acad. Sci. USA, 92, 7686-7689.
195. Pang, L., Sawada,T., Decker, S. J., Saltiel, A. R. (1995). Inhibition of MAP kinase kinase blocks the differentiation of PC-12 cells induced by nerve growth factor. J. Biol. Chem., 270, 13585-13588.
196. Waters, S. B., Holt, K. H., Ross, S. E., Syu, L. J., Guan, K. L., Saltiel, A. R., Koretzky, G. A., Pessin, J. E. (1995). Desensitization of Ras activation by a feedback disassociation of the SOS-Grb2 complex. J. Biol. Chem., 270, 20883-20886.
197. Langlois,W. J., Sasaoka,T., Saltiel, A. R., Olefsky, J. M. (1995). Negative feedback regulation and desensitization of insulin-and epidermal growth factor-stimulated p21ras activation. J. Biol. Chem., 270, 25320-25323.
198. Alessi,D. R., Cuenda,A., Cohen, P., Dudley,D. T., Saltiel,A. R. (1995). PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J. Biol. Chem., 270, 27489-27494.
199. Kültz, D., Madhany, S., Burg, M. B. (1998). Hyperosmolality causes growth arrest of murine kidney cells. Induction of GADD45 and GADD153 by osmosensing via stress-activated protein kinase 2. J. Biol. Chem., 273, 13645-13651.
200. Kemp, B. E., Graves, D. J., Benjamini, E., Krebs, E. G. (1977). Role of multiple basic residues in determining the substrate specificity of cyclic AMP-dependent protein kinase. J. Biol. Chem., 252, 4888-4894.
201. Kemp, B. E., Pearson, R. B., House, C. M. (1991). Pseudosubstrate-based peptide inhibitors. Methods Enzymol., 201, 287-304.
202. Ablooglu, A. J., Till, J. H., Kim, K., Parang, K., Cole, P. A., Hubbard, S. R., Kohanski, R. A. (2000). Probing the catalytic mechanism of the insulin receptor kinase with a tetrafluorotyrosine-containing peptide substrate. J. Biol. Chem., 275, 30394-30398.
203. Niu, J., Lawrence, D. S. (1997). Nonphosphorylatable tyrosine surrogates. Implications for protein kinase inhibitor design. J. Biol. Chem., 272, 1493-1499.
204. Pargellis, C., Tong, L., Churchill, L., Cirillo, P. F., Gilmore, T., Graham, A. G., Grob, P. M., Hickey, E. R., Moss, N., Pav, S., Regan, J. (2002). Inhibition of p38 MAP kinase utilizing a novel allosteric binding site. Nat. Struct. Biol., 9, 268-272.
205. Nagar, B., Bornmann,W. G., Pellicena, P., Schindler,T.,Veach, D. R., Miller,W. T., Clarkson, B., Kuriyan, J. (2002). Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res., 62, 4236-4243.
206. Vu, C. B. (2000). Recent advances in the design and synthesis of SH2 inhibitors of Src, Grb2 and ZAP-70. Curr. Med. Chem., 7, 1081-1100.
207. Vu, C. B., Corpuz, E. G., Pradeepan, S. G., Violette, S., Bartlett, C., Sawyer, T. K. (1999). Nonpeptidic SH2 inhibitors of the tyrosine kinase ZAP-70. Bioorg. Med. Chem. Lett., 9, 3009-3014.
208. Muller, G. (2000). Peptidomimetics SH2 domain antagonists for targeting signal transduction. Topics Curr. Chem., 211, 17-59.
209. Vu, C. B., Corpuz, E. G., Merry, T. J., Pradeepan, S. G., Bartlett, C., Bohacek, R. S., Botfield, M. C., Eyermann, C. J., Lynch, B. A., MacNeil, I. A., Ram, M. K., van Schravendijk, M. R., Violette, S., Sawyer, T. K. (1999). Discovery of potent and selective SH2 inhibitors of the tyrosine kinase ZAP-70. J. Med. Chem., 42, 4088-4098.
210. Cody,W. L., Lin, Z., Panek, R. L., Rose,D.W., Rubin, J. R. (2000). Progress in the development of inhibitors of SH2 domains. Curr. Pharm. Des., 6, 59-98.
211. Broom,A. D. (1989). Rational design of enzyme inhibitors: Multisubstrate analog inhibitors. J. Med. Chem., 32, 2-7.
212. Page, M. I., Jencks,W. P. (1971). Entropic contributions to rate accelerations in enzymic and intramolecular reactions and the chelate effect. Proc. Natl.Acad. Sci. USA, 68, 1678-1683.
213. Bruice, T. C., Benkovic, S. J. (2000). Chemical basis for enzyme catalysis. Biochemistry, 30, 6267-6274.
214. Parang, K., Cole, P. A. (2002). Bisubstrate inhibitors of protein kinases. Pharmacol. Ther., 93, 1-13.
215. Kruse, C. H., Holden, K. G., Pritchard, M. L., Field, J. A., Rieman, D. J., Greig, R. G., Poste, G. (1988). Synthesis and evaluation of multisubstrate inhibitors of an oncogene-encoded tyrosine-specific protein kinase. J. Med. Chem., 31, 1762-1767.
216. Ricouart, A., Gesquiere, J. C., Tartar, A., Sergheraert, C. (1991). Design of potent protein-kinase inhibitors using the bisubstrate approach. J. Med. Chem., 34, 73-78.
217. Traxler, P. M., Wacker, O., Bach, H. L., Geissler, J. F., Kump, W., Meyer, T., Regenass, U., Roesel, J. L., Lydon, N. (1991). Sulfonylbenzoyl-nitrostyrenes: Potential bisubstrate type inhibitors of the EGF-receptor tyrosine protein kinase. J. Med. Chem., 34, 2328-2337.
218. Uri, A., Järlebark, L., von Kügelgen, I., Schöberg, T., Undén, A., Heibronn, E. (1994). A new class of compounds, peptide derivatives of adenosine 5¢-carboxylic acid, includes inhibitors of ATP receptor-mediated responses. Biorg. Med. Chem., 2, 1099-1105.
219. Uri, A., Raidaru, G., Subbi, J., Padari, K., Pooga, M. (2002). Identification of the ability of highly charges nanomolar inhibitors of protein kinases to cross plasma membranes and carry a protein into cells. Bioorg. Med. Chem. Lett., 12, 2117-2120.
220. Loog, M., Uri, A., Raidaru, G., Järv, J., Ek, P. (2000). Bi-substrate analog ligands for affinity chromatography of protein kinases. FEBS Lett., 480, 244-248.
221. Medzihradszky,D., Chen, S. L.,Kenyon,G. L., Gibson, B. (1994). Solid-phase synthesis of adenosine phosphopeptides as potential bisubstrate inhibitors of protein kinases. J. Am. Chem. Soc., 116, 9413-9419.
222. Profit,A. A., Lee,T. R., Lawrence,D. S. (1999). Bivalent inhibitors of protein tyrosine kinases. J. Am. Chem. Soc., 121, 280-283.
223. Cowburn, D., Zheng, J., Xu, Q., Barany, G. (1995). Enhanced affinities and specificities of consolidated ligands for the Src homology SH3 and SH2 domains of Abelson protein-tyrosine kinase. J. Biol. Chem., 270, 26738-26741.
224. Parang, K., Till, J. H., Ablooglu, A. J., Kohanski, R. A., Hubbard, S. R., Cole, P. A. (2001). Mechanism-based design of a protein kinase inhibitor. Nat. Struct. Biol., 8, 37-41.
225. Tanoue, T., Nishida, E. (2002). Docking interactions in the mitogen-activated protein kinase cascades. Pharmacol. Ther., 93, 193-202.
226. Chang, C. I., Xu, B. E., Akella, R., Cobb, M. H., Goldsmith, E. J. (2002). Crystal structures of MAP kinase p38 complexed to the docking sites on its nuclear substrate MEF2A and activator MKK3b. Mol. Cell., 9, 1241-1249.
227. Ho, D. T., Bardwell, A. J., Abdollahi, M., Bardwell, L. (2003). A docking site in MKK4 mediates high affinity binding to JNK MAPKs and competes with similar docking sites in JNK substrates. J. Biol. Chem., 278, 32662-32672.
228. Lee, S., Lin, X., Nam, N. H., Parang, K., Sun, G. (2003). Determination of the substrate-docking site of protein tyrosine kinase C-terminal Src kinase. Proc. Natl. Acad. Sci. USA, 100, 14707-14712.
229. Denny,W. A. (2002). Irreversible inhibitors of the erbB family of protein tyrosine kinases. Pharmacol. Ther., 93, 253-261.
230. Allen, L. F., Eiseman, I. A., Fry, D. W., Lenehan, P. F. (2003). CI-1033, an irreversible pan-erbB receptor inhibitor and its potential application for the treatment of breast cancer. Semin. Oncol., 30(5, Suppl. 16), 65-78.
231. Wissner, A., Overbeek, E., Reich, M. F., Floyd, M. B., Johnson, B. D., Mamuya, N., Rosfjord, E. C., Discafani, C., Davis, R., Shi, X., Rabindran, S. K., Gruber, B. C., Ye, F., Hallett, W. A., Nilakantan, R., Shen, R., Wang, Y. F., Greenberger, L. M., Tsou, H. R. (2003). Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2). J. Med. Chem., 46, 49-63.
232. Sreedhar, A. S., Soti, C., Csermely, P. (2004). Inhibition of Hsp90: A new strategy for inhibiting protein kinases. Biochim. Biophys. Acta, 1697, 233-242.
233. Neckers. L. (2002). Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol. Med., 8, S55-S61.
234. Nimmanapalli, R., O'Bryan, E., Kuhn, D., Yamaguchi, H., Wang, H. G., Bhalla, K. N. (2003). Regulation of 17-AAG-induced apoptosis: Role of Bcl-2, Bcl-xL, and Bax downstream of 17-AAG-mediated downregulation of Akt, Raf-1 and Src kinases. Blood, 102, 269-275.
235. Masui, H., Kawamoto, T., Sato, J. D., Wolf, B., Sato, G., Mendelsohn, J. (1984). Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor antibodies. Cancer Res., 44, 1002-1007.
236. Slamon, D. J., Clark G. M.,Wong, S. G., Levin,W. J., Ullrich, A., McGuire,W. L. (1987). Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235, 177-182.
237. Cho, H.-S., Mason, K., Ramyar, K. X., Stanley, A. M., Gabelli, S. B., Denney, Jr., D. W., Leahy, D. J. (2003). Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature, 421, 756-760.
238. Morin, M. J. (2000). From oncogene to drug: Development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents. Oncogene, 19, 6574-6583.
239. Cohen, M., H., Williams, G. A., Sridhara, R., Chen, G., Pazdur, R. (2003). FDA drug approval summary: Gefitinib (ZD1839) (Iressa) tablets. Oncologist, 8, 303-306.
240. Blagosklonny, M. V., Darzynkiewicz, Z. (2003). Why Iressa failed: Toward novel use of kinase inhibitors (outlook). Cancer Biol. Ther., 2, 137-140.
241. Dancey, J. E., Freidlin, B. (2003). Targeting epidermal growth factor receptor-Are we missing the mark? Lancet, 362, 62-64.
242. Azam, M., Latek, R. R., Daley, G. O. (2003). Mechanisms of autoinhibition and STI-571/Imatinib resistance revealed by mutagenesis of BCR-ABL. Cell, 112, 831-843.
243. Hidalgo, M., Siu, L. L., Nemunaitis, J., Rizzo, J., Hammond, L. A., Takimoto, C., Eckhardt, S. G., Tolcher, A., Britten, C. D., Denis, L., Ferrante, K., Von Hoff, D. D., Silberman, S., Rowinsky, E. K. (2001). Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J. Clin. Oncol., 19, 3267-3279.
244. Stamos, J., Sliwkowski, M. X., Eigenbrot, C. (2002). Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J. Biol. Chem., 277, 46265-46272.
245. Traxler, P., Bold, G., Buchdunger, E., Caravtti, G., Furet, P., Manley, P., O'Reilly, T., Wood, J., Zimmermann, J. (2001). Tyrosine kinase inhibitors: From rational design to clinical trials. Med. Res. Rev., 21, 499-512.
246. Tiseo, M., Loprevite, M., Ardizzoni, A. (2004). Epidermal growth factor receptor inhibitors: A new prospective in the treatment of lung cancer. Curr. Med. Chem. Anti-Cancer Agents, 4, 139-148.
247. Folkman, J. (1971).Tumor angiogenesis:Therapeutic implications. N. Engl. J.Med., 285, 1182-1186.
248. Giles, F. J. (2002). The emerging role of angiogenesis inhibitors in hematologic malignancies. Oncol. (Huntington), 16, 23-29.
249. Giles,F., Cooper,M.A., Silverman, L., Karp, J. E., Lancet, J. E., Zangari, M., Shami, P. J., Khan, K. D., Hannah, A. L., Cherrington, J. M., Thomas, D. A., Garcia-Manero, G., Albitar, M., Kantarjian, H. M., Stopeck, A. T. (2003). Phase II study of SU5416-A small-molecule, vascular endothelial growth factor tyrosine kinase receptor inhibitor-in patients with refractory myeloproliferative diseases. Cancer, 97, 1920-1928.
250. Hasselbalch, H. C. (2003). SU6668 in idiopathic myelofibrosis-A rational therapeutic approach targeting several tyrosine kinases of importance for the myeloproliferation and the development of bone marrow fibrosis and angiogenesis. Med. Hypoth., 61, 244-247.
251. Laird, A. D., Vajkoczy, P., Shawver, L. K., Thurnher, A., Liang, C., Mohammadi, M., Schlessinger, J., Ullrich, A., Hubbard, S. R., Blake, R. A., Fong, T. A., Strawn, L. M., Sun, L., Tang, C., Hawtin, R., Tang, F., Shenoy, N., Hirth, K. P., McMahon, G., Cherrington. (2000). SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res., 60, 4152-4160.
252. Breier, G., Blum, S., Peli, J., Groot, M.,Wild, C., Risau,W., Reichmann, E. (2002). Transforming growth factor-beta and Ras regulate the VEGF/VEGF-receptor system during tumor angiogenesis. Int. J. Cancer, 97, 142-148.
253. Ferrara, N. (2000). VEGF:An update on biological and therapeutic aspects. Curr. Opin. Biotechnol., 11, 617-624.
254. Ferrara,N. (2000).Vascular endothelial growth factor and the regulation of angiogenesis. Recent Prog. Horm. Res., 55, 15-35.
255. Ferrara, N., Gerber, H. P. (2001). The role of vascular endothelial growth factor in angiogenesis. Acta Haematol., 106, 148-156.
256. Kolch, W., Martiny-Baron, G., Kieser, A., Marme, D. (1995). Regulation of the expression of the VEGF/VPS and its receptors: Role in tumor angiogenesis. Breast Cancer Res. Treat., 36, 139-155.
257. Bold, G., Altmann, K. H., Frei, J., Lang, M., Manley, P.W., Traxler, P.,Wietfeld, B., Bruggen, J., Buchdunger, E., Cozens, R., Ferrari, S., Furet, P., Hofmann, F., Martiny-Baron, G., Mestan, J., Rosel, J., Sills, M., Stover, D., Acemoglu, F., Boss, E., Emmenegger, R., Lasser, L., Masso, E., Roth, R., Schlachter, C., Vetterli, W. (2000). New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis. J. Med. Chem., 43, 2310-2323.
258. Bold, G., Altmann, K. H., Frei, J., Lang, M., Manley, P.W., Traxler, P.,Wietfeld, B., Bruggen, J., Buchdunger, E., Cozens, R., Ferrari, S., Furet, P., Hofmann, F., Martiny-Baron, G., Mestan, J., Rosel, J., Sills, M., Stover, D., Acemoglu, F., Boss, E., Emmenegger, R., Lasser, L., Masso, E., Roth, R., Schlachter, C., Vetterli, W. (2000). New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis. J. Med. Chem., 43, 3200-3213.
259. Wood, J. M., Bold, G., Buchdunger, E., Cozens, R., Ferrari, S., Frei, J., Hofmann, F., Mestan, J., Mett, H., O'Reilly, T., Persohn, E., Rosel, J., Schnell, C., Stover, D., Theuer, A., Towbin, H.,Wenger, F.,Woods-Cook, K., Menrad, A., Siemeister, G., Schirner, M., Thierauch, K. H., Schneider, M. R., Drevs, J., Martiny-Baron, G., Totzke, F. (2000). PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res., 60, 2178-2189.
260. Smith, J. K., Mamoon, N. M., Duhe, R. J. (2004). Emerging roles of targeted small molecule protein-tyrosine kinase inhibitors in cancer therapy. Oncol. Res., 14, 175-225.
261. Mohammadi, M., Froum, S., Hamby, J. M., Schroeder, M. C., Panek, R. L., Lu, G. H., Eliseenkova,A.V., Green,D., Schlessinger, J., Hubbard, S. R. (1998). Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. EMBO J., 17, 5896-5904.
262. Fong, T. A., Shawver, L. K., Sun, L., Tang, C., App, H., Powell, T. J., Kim, Y. H., Schreck, R., Wang, X., Risau, W., Ullrich, A., Hirth, K. P., McMahon, G. (1999). SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res., 59, 99-106.
263. Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., Lydon, N. B. (1996). Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med., 2, 561-566.
264. Barnes,D. J., Melo, J.V. (2003). Management of chronic myeloid leukemia:Targets for molecular therapy. Semin. Hematol., 40, 34-49.
265. Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., Sawyers, C. L. (2001). Clinical resistance to STI-1571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science, 293, 876-880.
266. Roumiantsev, S., Shah, N. P., Gorre, M. E., Nicoll, J., Brasher, B. B., Sawyers, C. L., Van Etten, R. A. (2000). Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain Ploop. Proc. Natl. Acad. Sci. USA, 99, 10700-10705.
267. Buchdunger, E., Cioffi, C. L., Law, N., Stiver, D., Ohno-Jones, S., Druker, B. J., Lyndon, N. B. (2000). Abl protein-tyrosine kinase inhibitor ST1571 inhibits in vitro signal transduction mediated by c-Kit and platelet-derived growth factor receptors. J. Pharmacol. Exp. Ther., 295, 139-145.
268. Okuda, K.,Weisberg, E., Gilliland,D.G., Griffin, J.D. (2001). ARG tyrosine kinase activity is inhibited by ST1571. Blood, 97, 2440-2448.
269. van Oosterom, A. T., Judson, I., Verweij, J., Stroobants, S., Donato di Paola, E., Dimitrijevic, S., Martens, M.,Webb, A., Sciot, R.,Van Glabbeke, M., Silberman, S., Nielsen,O. S. European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. (2001). Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: A phase I study. Lancet, 358, 1421-1423.
270. Blanke, C. D., Eisenberg, B. L., Heinrich, M. C. (2001). Gastrointestinal stromal tumors. Curr. Treat. Options Oncol., 2, 485-491.
271. Heinrich, M. C., Griffith, D. J., Druker, B. J.,Wait, C. L., Ott, K. A., Zigler, A. J. (2000). Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood, 96, 925-932.
272. Nagar, B., Hantschel, O., Young, M. A., Scheffzek, K., Veach, D., Bornmann,W., Clarkson, B., Superti-Furga,G., Kuriyan, J. (2003). Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell, 112, 859-871.
273. Noble, M. E., Endicott, J. A., Johnson, L. N. (2004). Protein kinase inhibitors: Insights into drug design from structure. Science, 303, 1800-1805.
274. Blencke, S., Zech, B., Engkvist, O., Greff, Z., Orfi, L., Keri, G., Ullrich, A., Daub, H. (2004). Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors. Chem. Biol., 11, 691-701.
275. Blencke, S., Ullrich, A., Daub, H. (2003). Mutation of threonine 766 in the epidermal growth factor receptor reveals a hotspot for resistance formation against selective tyrosine kinase inhibitors. J. Biol. Chem., 278, 15435-15440.
276. Wisniewski, D., Lambek, C. L., Liu, C., Strife, A., Veach, D. R., Nagar, B., Young, M. A., Schindler, T., Bornmann, W. G., Bertino, J. R., Kuriyan, J., Clarkson, B. (2002). Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases. Cancer Res., 62, 4244-4255.
277. Dalgarno, D. C., Botfield, M. C., Rickles, R. J. (1998). SH3 domains and drug design: Ligands, structure, and biological function. Biopolymers, 43, 383-400.
278. Kuriyan, J., Cowburn, D. (1997). Molecular peptide recognition domains in eukaryotic signaling. Annu. Rev. Biophys. Biomol. Struct., 26, 259-288.
279. Gilmer,T., Rodriguez, M., Jordan, S., Crosby, R., Alligood, K., Green, M., Kimery, M., Wagner, C., Kinder, D., Charifson, P. (1994). Peptide inhibitors of src SH3-SH2-phosphoprotein interactions. J. Biol. Chem., 269, 31711-31719.
280. Waksman, G., Kominos, D., Robertson, S. C., Pant, N., Baltimore, D., Birge, R. B., Cowburn, D., Hanfusa, H., Majer, B. J., Overduin, M., Resh, M. D., Rios, C. B., Silverman, L., Kuriyan, J. (1992). Crystal structure of the phosphotyrosine recognition domain SH2 of v-src complexed with tyrosine-phosphorylated peptides. Nature, 358, 646-653.
281. Waksman, G., Shoelson, S. E., Pant, N., Cowburn, D., Kuriyan, J. (1993). Binding of a high affinity phosphotyrosyl peptide to the Src SH2 domain: Crystal structures of the complexed and peptide-free forms. Cell, 72, 779-789.
282. Eck, M. J., Shoelson, S. E., Harrison, S. C. (1993). Recognition of a high-affinity phosphotyrosyl peptide by the Src homology-2 domain of p56lck. Nature, 362, 87-91.
283. Grucza, R. A., Bradshaw, J. M., Futterer, K.,Waksman, G. (1999). SH2 domains: From structure to energetics, a dual approach to the study of structure-function relationships. Med. Res. Rev., 19, 273-299.
284. Bradshaw, J. M., Mitaxov, V.,Waksman, G. (1999). Investigation of phosphotyrosine recognition by the SH2 domain of the Src kinase. J. Mol. Biol., 293, 971-985.
285. Park, J., Fu, H., Pei,D. (2003). Peptidyl aldehydes as reversible covalent inhibitors of Src homology 2 domains. Biochemistry, 42, 5159-5167.
286. Marseigne, I., Roques, B. P. (1988). Synthesis of new amino acids mimicking sulfated and phosphorylated tyrosine residues. J. Org. Chem., 53, 3621-3624.
287. Burke, T. R., Jr., Russ, P., Lim, B. (1991). Preparation of 4-[bis(tert-butoxy)phosphorylmethyl]-N-(fluoren-9-ylmethoxycarbonyl)-dl-phenylalanine. A hydrolytically stable analog of O-phosphotyrosine potentially suitable for peptide synthesis. Synthesis, 11, 1019-1020.
288. Shoelson, S. E., Chatterjee, S., Chaudhuri, M., Burke,T. R., Jr. (1991). Solid-phase synthesis of nonhydrolyzable phosphotyrosyl peptide analogs with Na-Fmoc-(O,O-di-tert-butyl)phosphono-p-methylphenylalanine. Tet. Lett., 32, 6061-6064.
289. Smyth, M. S., Ford, H., Jr., Burke,T. R. Jr. (1992). A general method for the preparation of benzylic a,a-difluorophosphonic acids; non-hydrolyzable mimetics of phosphotyrosine. Tetrahedr. Lett., 33, 4137-4140.
290. Burke,T. R., Jr., Smyth, M. S., Nomizu, M., Otaka, A., Roller, P. R. (1993). Preparation of fluoro-and hydroxy-4-(phosphonomethyl)-d,l-phenylalanine suitably protected for solid-phase synthesis of peptides containing hydrolytically stable analogs of O-phosphotyrosine. J. Org. Chem., 58, 1336-1340.
291. Burke, T. R., Jr, Smyth, M. S., Otaka, A., Nomizu, M., Roller, P. P.,Wolf, G., Case, R., Shoelson, S. E. (1994). Nonhydrolyzable phosphotyrosyl mimetics for the preparation of phosphatase-resistant SH2 domain inhibitors. Biochemistry, 33, 6490-6494.
292. Yao, Z. J., King, C. R., Cao,T., Kelley, J., Milne, G.W. A.,Voigt, J. H., Burke,T. R. (1999). Potent inhibition of Grb2 SH2 domain binding by non-phosphatecontaining ligands. J. Med. Chem., 42, 25-35.
293. Shahripour, A., Plummer, M. S., Lunney, E. A., Para, K. S., Stankovic, C. J., Rubin, J. R., Humblet, C., Fergus, J. H., Marks, J. S., Herrera, R., Hubbell, S. E., Saltiel, A. R., Sawyer, T. K. (1996). Novel phosphotyrosine mimetics in the design of peptide ligands for pp60(src) SH2 domain. Bioorg. Med. Chem. Lett., 6, 1209-1214.
294. Sundaramoorthi, R., Kawahata, N., Yang, M. G., Shakespeare, W. C., Metcalf, C. A. III,Wang,Y., Merry,T., Eyermann,C. J., Bohacek, R. S., Narula, S., Dalgarno, D. C., Sawyer,T. K. (2003). Structure-based design of novel nonpeptide inhibitors of the Src SH2 domain: Phosphotyrosine mimetics exploiting multifunctional group replacement chemistry. Biopolymers, 71, 717-729.
295. Ye, B., Akamatsu, M., Shoelson, S. E., Wolf, G., Giorgetti-Peraldi, S., Yan, X., Roller, P. P., Burke, T. R., Jr. (1995). l-O-(2-Malonyl)tyrosine: A new phosphotyrosyl mimetic for the preparation of Src homology 2 domain inhibitory peptides. J. Med. Chem., 38, 4270-4275.
296. Burke, T. R., Yao, Z. J., Zhao, H., Milne, G. W. A., Wu, L., Zhang, Z. Y., Voigt, J. H. (1998). Enantioselective synthesis of nonphosphorus-containing phosphotyrosyl mimetics and their use in the preparation of tyrosine phosphatase inhibitory peptides. Tetrahedron, 54, 9981-9994.
297. Gao, Y., Burke, T. R. (2000). Stereoselective preparation of l-4-(2¢-malonyl)phenylalanine suitably protected for Fmoc-based synthesis of potent signal transduction inhibitory ligands. Synlett, 1, 134-136.
298. Tong, L.,Warren,T. C., Lukas, S., Schembri-King, J., Betageri, R., Proudfoot, J. R., Jakes, S. (1998). Carboxymethyl-phenylalanine as a replacement for phosphotyrosine in SH2 domain binding. J. Biol. Chem., 273, 20238-20242.
299. Nam, N. H., Pitts, R., Sun, G., Sardari, S., Tiemo, A., Xie, M., Yan, B., Parang, K. (2004). Design of tetrapeptide ligands as inhibitors of the Src SH2 domain. Bioorg. Med. Chem., 12, 779-787.
300. Nam, N. H., Ye, G., Sun, G., Parang, K. (2004). Conformationally constrained peptide analogues of pTyr-Glu-Glu-Ile as inhibitors of the Src SH2 domain binding. J. Med. Chem., 47, 3131-3141.
301. Alfaro-Lopez, J., Yuan,W., Phan, B., Kamath, J., Lou, Q., Lam, K. S., Hruby, V. J. (1998). Discovery of a novel series of potent and selective substrate-based inhibitors of p60c-src protein tyrosine kinase: Conformational and topographical constraints in peptide design. J. Med. Chem., 41, 2252-2260.
302. Lou, Q., Leftwich, M. E., McKay, R. T., Salmon, S. E., Rychetsky, L., Lam, K. S. (1997). Potent pseudosubstrate-based peptide inhibitors for p60c-src protein tyrosine kinase. Cancer Res., 57, 1877-1881.
303. Kamath, J. R., Liu, R., Enstrom, A. M., Lou, Q., Lam, K. S. (2003). Development and characterization of potent and specific peptide inhibitors of p60c-src protein tyrosine kinase using pseudosubstrate-based inhibitor design approach. J. Peptide Res., 62, 260-268.
304. Metcalf, C. A. III, van Schravendijk, M. R., Dalgarno, D. C., Sawyer,T. K. (2002). Targeting protein kinases for bone disease: Discovery and development of Src inhibitors. Curr. Pharm. Des., 8, 2049-2075.
305. Sundaramoorthi, R., Shakespeare,W. C., Keenan, T. P., Metcalf, III C. A.,Wang, Y., Mani, U.,Taylor, M., Liu, S., Bohacek, R. S., Narula, S. S., Dalgarno, D. C.,Van Schravandijk, M. R.,Violette, S. M., Liou, S., Adams, S., Ram, M. K., Keats, J. A., Weigele, M., Sawyer, T. K. (2003). Bone-targeted Src kinase inhibitors: Novel pyrrolo-and pyrazolopyrimidine analogues. Bioorg. Med. Chem. Lett., 13, 3063-3066.
306. Sawyer, T. K., Bohacek, R. S., Eyermann, C. J., Kawahata, N., Metcalf, III, C. A., Shakespeare,W. C., Sundaramoorthi, R.,Wang,Y.,Yang, M. G. (2002). Mini-Rev. Med. Chem., 2, 475-489.
307. Uehara,Y., Hori, M., Takeuchi, T., Umezawa, H. (1986). Phenotypic change from transformed to normal induced by benzoquinonoid ansamycins accompanies inactivation of p60src in rat kidney cells infected with Rous sarcoma virus. Mol. Cell. Biol., 6, 2198-2206.
308. Murakami, Y., Mizuno, S., Hori, M., Uehara, Y. (1988). Reversal of transformed phenotypes by herbimycin A in src oncogene expressed rat fibroblasts. Cancer Res., 48, 1587-1590.
309. Kwon, H. J., Yoshida, M., Fukui, Y., Horinouchi, S., Beppu, T. (1992). Potent and specific inhibition of p60 v-src protein kinase both in vivo and in vitro by radicicol. Cancer Res., 52, 6926-6930.
310. Bishop, A. C., Shokat, K. M. (1999). Acquisition of inhibitor-sensitive protein kinases through protein design. Pharmacol. Ther., 82, 337-346.
311. Blake, R. A., Broome, M. A., Liu, X.,Wu, J., Gishizky, M., Sun, L., Courtneidge, S. A. (2000). SU6656, a selective src family kinase inhibitor, used to probe growth factor signaling. Mol. Cell Biol., 20, 9018-9027.
312. Tatoon, L., Molrey,G. M., Chopra, R., Khwaja,A. (2003). The Src-selective kinase inhibitor PP1 also inhibits kit and Bcr-Abl tyrosine kinases. J. Biol. Chem., 278, 4847-4853.
313. Dorsey, J. F., Jove, R., Kraker, A. J.,Wu, J. (2000). The pyrido[2,3-d-]pyrimidine derivative PD180970 inhibits p210Bcr-Abl tyrosine kinase and induces apoptosis of K562 leukemic cells. Cancer Res., 60, 3127-3131.
314. Faltynek, C. R., Schroeder, J., Mauvais, P., Miller, D.,Wang, S., Murphy, D., Lehr, R., Kelley, M., Maycock, A., Michne, W., Miski, M., Thunberg, A. L. (1995). Damnacanthal is a highly potent, selective inhibitor of p56lck tyrosine kinase activity. Biochemistry, 34, 12404-12410.
315. Huang, C. K., Wu, F. Y., Ai, Y. X. (1995). Polyhydroxylated 3-(N-phenyl) carbamoyl-2-iminochromene derivatives as potent inhibitors of tyrosine kinase p60c-src. Bioorg. Med. Chem. Lett., 5, 2423-2428.
316. Vermeulen, K. D., Van Bockstaele, R., Berneman, Z. N. (2003). The cell cycle:A review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif., 36, 131-149.
317. Senderowicz, A. M. (2002). Cyclin-dependent kinases as targets for cancer therapy. Cancer Chemother. Biol. Response Modif., 20, 169-196.
318. Dai, Y., Grant, S. (2003). Cyclin-dependent kinase inhibitors. Curr. Opin. Pharmacol., 3, 362-370.
319. Anchan, R. M., Reh, T. A., Angello, J., Balliet, A.,Walker, M. (1991). EGF and TGF-alpha stimulate retinal neuroepithelial cell proliferation in vitro. Neuron, 6, 923-936.
320. Han, J., Lee J. D., Bibbs, L., Ulevitch, R. J. (1994). A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science, 265, 808-811.
321. Jiang, Y., Chen, C., Li, Z., Guo,W., Gegner, J. A., Lin, S., Han, J. (1996). Characterization of the structure and function of a new mitogen-activated protein kinase (p38beta). J. Biol. Chem., 271, 17920-17926.
322. Li, Z., Jiang, Y., Ulevitch, R. J., Han, J. (1996). The primary structure of p38 gamma: A new member of p38 group of MAP kinases. Biochem. Biophys. Res. Commun., 228, 334-340.
323. Gallagher,T. F., Seibel,G. L., Kassis, S., Laydon, J. T., Blumenthal, M. J., Lee, J. C., Lee, D., Boehm, J. C., Fier-Thompson, S. M., Abt, J.W., Soreson, M. E., Smietana, J. M., Hall, R. F., Garigipati, R. S., Bender, P. E., Erhard, K. F., Krog, A. J., Hofmann,G. A., Sheldrake,P. L., McDonnell,P. C.,Kumar, S.,Young,P. R.,Adams, J. L. (1997). Regulation of stress-induced cytokine production by pyridinylimidazoles; inhibition of CSBP kinase. Bioorg. Med. Chem., 5, 49-64.
324. Adams, J. L., Boehm, J. C., Kassis, S., Gorycki, P. D., Webb, E. F., Hall, R., Sorenson, M., Lee, J. C., Ayrton, A., Griswold, D. E., Gallagher, T. F. (1998). Pyrimidinylimidazole inhibitors of CSBP/p38 kinase demonstrating decreased inhibition of hepatic cytochrome P450 enzymes. Bioorg. Med. Chem. Lett., 8, 3111-3116.
325. de Laszlo, S. E., Visco, D., Agarwal, L., Chang, L., Chin, J., Croft, G., Forsyth, A., Fletcher, D., Frantz, B., Hacker, C., Hanlon, W., Harper, C., Kostura, M., Li, B., Luell, S., MacCoss, M., Mantlo, N., O'Neill, E. A., Orevillo, C., Pang, M., Parsons, J., Rolando, A., Sahly,Y., Sidler, K., O'Keefe, S. J. (1998). Pyrroles and other heterocycles as inhibitors of p38 kinase. Bioorg. Med. Chem. Lett., 8, 2689-2694.
326. Revesz, L., Di Padova, F. E., Buhl,T., Feifel, R., Gram, H., Hiestand, P., Manning, U., Zimmerlin, A. G. (2000). SAR of 4-hydroxypiperidine and hydroxyalkyl substituted heterocycles as novel p38 map kinase inhibitors. Bioorg. Med. Chem. Lett., 10, 1261-1264.
327. Fijen, J. W., Zijlstra, J. G., De Boer, P., Spanjersberg, R., Tervaert, J. W., Van Der Werf, T. S., Ligtenberg, J. J., Tulleken, J. E. (2001). Suppression of the clinical and cytokine response to endotoxin by RWJ-67657, a p38 mitogen-activated proteinkinase inhibitor, in healthy human volunteers. Clin. Exp. Immunol., 124, 16-20.
328. Wadsworth, S. A., Cavender, D. E., Beers, S. A., Lalan, P., Schafer, P. H., Malloy, E. A.,Wu,W., Fahmy,B., Olini,G. C., Davis, J. E., Pellegrino-Gensey, J. L.,Wachter, M. P., Siekierka, J. J. (1999). RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase. J. Pharmacol. Exp. Ther., 291, 680-687.
329. Collis, A. J., Foster, M. L., Halley, F., Maslen, C., McLay, I. M., Page, K. M., Redford, E. J., Souness, J. E.,Wilsher, N. E. (2001). RPR203494 a pyrimidine analogue of the p38 inhibitor RPR200765A with an improved in vitro potency. Bioorg. Med. Chem. Lett., 11, 693-696.
330. Mclay, L. M., Halley, F., Souness, J. E., McKenna, J., Benning, V., Birrell, M., Burton, B., Belvisi, M., Collis, A., Constan, A., Foster, M., Hele, D., Jayyosi, Z., Kelley, M., Maslen, C.,Miller, G., Ouldelhkim, M. C., Page, K., Phipps, S., Pollock, K., Porter, B., Ratcliffe, A. J., Redford, E. J., Webber, S., Slater, B., Thybaud, V., Wilsher, N. (2001). The discovery of RPR 200765A, a p38 MAP kinase inhibitor displaying a good oral antiarthritic efficacy. Bioorg. Med. Chem., 9, 537-554.
331. Ge, B., Gram, H., Di Padova, F., Huang, B., New, L., Ulevitch, R. J., Luo,Y., Han, J. (2002). MAPKK-independent activation of p38alpha mediated by TAB1-dependent autophosphorylation of p38alpha. Science, 295, 1291-1294.
332. Lee, J. C., Laydon, J. T., McDonnell, P. C., Gallagher, T. F., Kumar, S., Green, D., McNulty, D., Blumenthal, M. J., Heys, J. R., Landvatter, S. W., Strickler, J. E., McLaughlin, M. M., Siemens, I. R., Fisher, S. M., Livi, G. P.,White, J. R., Adams, J. L., Young, P. R. (1994). A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature, 372, 739-746.
333. Purves, T., Middlemas, A., Agthong, S., Jude, E. B., Boulton, A. J., Fernyhough, P., Tomlinson, D. R. (2001). A role for mitogen-activated protein kinases in the etiology of diabetic neuropathy. FASEB J., 15, 2508-2514.
334. Igarashi, M., Wakasaki, H., Takahara, N., Ishii, H., Jiang, Z. Y., Yamauchi, T., Kuboki, K., Meier, M., Rhodes, C. J., King, G. L. (1999). Glucose or diabetes activates p38 mitogen-activated protein kinase via different pathways. J. Clin. Invest., 103, 185-195.
335. Manson, M. M., Holloway, K. A., Howells, L. M., Hudson, E. A., Plummer, S. M., Squires, M. S., Prigent, S. A. (2000). Modulation of signal-transduction pathways by chemopreventive agents. Biochem. Soc. Trans., 28, 7-12.
336. Ding, Q.,Wang, Q., Evers, B. M. (2001). Alterations of MAPK activities associated with intestinal cell differentiation. Biochem. Biophys. Soc. Trans., 284, 282-288.
337. Andreakos, E. (2003).Targeting cytokines in autoimmunity: New approaches, new promise. Expert Opin. Biol. Ther., 3, 435-447.
338. Branger, J., van den Blink, B.,Weijer, S., Gupta, A., van Deventer, S. J., Hack, C. E., Peppelenbosch, M. P., van der Poll, T. (2003). Inhibition of coagulation, fibrinolysis, and endothelial cell activation by a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. Blood, 101, 4446-4448.
339. Jackson, P. F., Bullington, J. L. (2002). Pyridinylimidazole based p38 MAP kinase inhibitors. Curr. Topics Med. Chem., 2, 1011-1020.
340. Cirillo, P. F., Pargellis, C., Regan, J. (2002). The non-diaryl heterocycle classes of p38 MAP kinase inhibitors. Curr. Topics Med. Chem., 2, 1021-1035.
341. Regan, J., Capolino, A., Cirillo, P. F., Gilmore,T., Graham, A. G., Hickey, E., Kroe, R. R., Madwed, J., Moriak, M., Nelson, R., Pargellis,C. A., Swinamer,A.,Torcellini, C., Tsang, M., Moss, N. (2003). Structure-activity relationships of the p38alpha MAP kinase inhibitor 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]urea (BIRB 796). J. Med. Chem., 46, 4676-4686.
342. Barone, F. C., Irving, E. A., Ray, A. M., Lee, J. C., Kassis, S., Kumar, S., Badger, A. M., Legos, J. J., Erhardt, J. A., Ohlstein, E. H., Hunter, A. J., Harrison, D. C., Philpott, K., Smith, B. R., Adams, J. L., Parsons, A. A. (2001). Inhibition of p38 mitogen-activated protein kinase provides neuroprotection in cerebral focal ischemia. Med. Res. Rev., 21, 129-145.
343. Hardy, L. W., Malikayil, A. (December 2003). The Impact of Structure-Guided Drug Design on Clinical Agents. www.currentdrugdiscovery.com, 15.
344. Cuenda, A., Rouse, J., Doza, Y. N., Meier, R., Cohen, P., Gallagher, T. F., Young, P. R., Lee, J. C. (1995). SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett., 364, 229-233.
345. Gao, F., Yue, T. L., Shi, D. W., Christopher, T. A., Lopez, B. L., Ohlstein, E. H., Barone, F. C., Ma, X. L. (2002). p38 MAPK inhibition reduces myocardial reperfusion injury via inhibition of endothelial adhesion molecule expression and blockade of PMN accumulation. Cardiovasc. Res., 53, 414-422.
346. Harper, S. J., LoGrasso, P. (2001). Inhibitors of the JNK signaling pathway. Drugs Future, 26, 957-973.
347. Bennett, B., Sasaki, D., Murray, B., O'leary, E., Sakata, S., Xu,W., Leisten, J. C., Motiwala, A., Pierce, S., Satoh, Y., Bhagwat, S. S., Manning, A. M., Anderson, D.W. (2001). SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc. Natl. Acad. Sci. USA, 98, 13681-13686.
348. Schnabl, B., Bradham, C. A., Bennett, B. L., Manning, A. M., Stefanovic, B., Brenner, D. A. (2001). TAK1/JNK and p38 have opposite effects on rat hepatic stellate cells. Hepatology, 34, 953-963.
349. Goss, G. G., Jiang, L., Vandorpe, D. H., Kieller, D., Chernova, M. N., Robertson, M., Alper, S. L. (2001). Role of JNK in hypertonic activation of Cl--dependent Na+/H+ exchange in Xenopus oocytes. Am. J. Physiol., 281, 1978-1990.
350. Rubinfeld, H., Seger, R. (2004). The ERK cascade as a prototype of MAPK signaling pathways. Methods Mol. Biol., 250, 1-28.
351. Brown, E. J., Beal, P. A., Keith, C. T., Chen, J., Shin, T. B., Schreiber, S. L. (1995). Control of p70 s6 kinase by kinase activity of FRAP in vivo. Nature, 377, 441-446.
352. Kimball, S. D.,Webster, K. R. (2001). Cell cycle kinases and checkpoint regulation in cancer. In A. M. Doherty (Ed.), Annual Reports in Medicinal Chemistry. Academic, San Diego,Vol. 36, pp. 139-148.
353. Webster K. R., Kimball S. D. (2000). Novel drugs targeting the cell cycle. Emerg. Drugs, 5, 45-59.
354. Ikuta, M., Kamata, K., Fukasawa, K., Honma, T., Machida, T., Hirai, H., Suzuki-Takahashi, I., Hayama, T., Nishimura, S. (2001). Crystallographic approach to identification of cyclin-dependent kinase 4 (CDK4)-specific inhibitors by using CDK4 mimic CDK2 protein. J. Biol. Chem., 276, 27548-27554.
355. Carini, D. J., Kaltenbach, R. F., Liu, J., Benfield, P. A., Boylan, J., Boisclair, M., Brizuela, L., Burton, C. R., Cox, S., Grafstrom, R., Harrison, B. A., Harrison, K., Akamike, E., Markwalder, J. A., Nakano, Y., Seitz, S. P., Sharp, D. M., Trainor, G. L., Sielecki, T. M. (2001). Identification of selective inhibitors of cyclin dependent kinase 4. Bioorg. Med. Chem. Lett., 11, 2209-2211.
356. Honma, T., Hayashi, K., Aoyama, T., Hashimoto, N., Machida, T., Fukasawa, K., Iwama, T., Ikeura, C., Ikuta, M., Suzuki-Takahashi, I., Iwasawa, Y., Hayama, T., Nishimura, S., Morishima, H. (2001). Structure-based generation of a new class of potent Cdk4 inhibitors: New de novo design strategy and library design. J. Med. Chem., 44, 4615-4627.
357. Honma, T., Yoshizumi, T., Hashimoto, N., Hayashi, K., Kawanishi, N., Fukasawa, K., Takaki, T., Ikeura, C., Ikuta, M., Suzuki-Takahashi, I., Hayama, T., Nishimura, S., Morishima, H. (2001). A novel approach for the development of selective Cdk4 inhibitors: Library design based on locations of Cdk4 specific amino acid residues. J. Med. Chem., 44, 4628-4640.
358. Fry,D.W., Bedford,D. C., Harvey, P. H., Fritsch, A.,Keller, P. R.,Wu, Z., Dobrusin, E., Leopold,W. R., Fattaey, A., Garrett, M. D. (2001). Cell cycle and biochemical effects of PD 0183812. A potent inhibitor of the cyclin D-dependent kinases CDK4 and CDK6. J. Biol. Chem., 276, 16617-16623.
359. Soni, R., Muller, L., Furet, P., Schoepfer, J., Stephan, C., Zumstein-Mecker, S., Fretz, H., Chaudhuri, B. (2000). Inhibition of cyclin-dependent kinase 4 (Cdk4) by fascaplysin, a marine natural product. Biochem. Biophys. Res. Commun., 275, 877-884.
360. Soni, R., O'Reilly,T., Furet, P., Muller, L., Stephan, C., Zumstein-Mecker, S., Fretz, H., Fabbro, D., Chaudhuri, B. J. (2001). Selective in vivo and in vitro effects of a small molecule inhibitor of cyclin-dependent kinase 4. Natl. Cancer Inst., 93, 436-446.
361. Knockaert, M., Greengard, P., Meijer, L. (2002). Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol. Sci., 23, 417-425.
362. Jeong, H. W., Kim, M. R., Son, K. H., Han, M. Y., Ha, J. H., Garnier, M., Meijer, L., Kwon,B. M. (2000). Cinnamaldehydes inhibit cyclin dependent kinase 4/cyclin D1. Bioorg. Med. Chem. Lett., 10, 1819-1822.
363. Meijer, L., Leclerc, S., Leost, M. (1999). Properties and potential-applications of chemical inhibitors of cyclin-dependent kinases. Pharmacol. Ther., 82, 279-284.
364. Fischer, P. M., Gianella-Borradori, A. (2003). CDK inhibitors in clinical development for the treatment of cancer. Exp. Opin. Invest. Drugs, 12, 955-970.
365. Zhai, S., Senderowicz, A. M., Sausville, E. A., Figg,W. D. (2002). Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development. Ann. Pharmacother., 36, 905-911.
366. Leclerc, S., Garnier, M., Hoessel, R., Marko, D., Bibb, J. A., Snyder, G. L., Greengard, P., Biernat, J.,Wu,Y. Z., Mandelkow, E. M., Eisenbrand,G., Meijer, L. (2001). Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors? J. Biol. Chem., 276, 251-260.
367. Meijer, L., Raymond, E. (2003). Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials. Acc. Chem. Res., 36, 417-425.
368. Vesely, J., Havlicek, L., Strnad, M., Blow, J. J., Donella-Deana, A., Pinna, L., Letham, D. S., Kato, J., Detivaud, L., Leclerc, S. (1994). Inhibition of cyclindependent kinases by purine analogues. Eur. J. Biochem., 224, 771-786.
369. Meijer, L., Borgne, A., Mulner,O., Chong, J. P., Blow, J. J., Inagaki, N., Inagaki, M., Delcros, J. G., Moulinoux, J. P. (1997). Biochemical and cellular effects of Roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur. J. Biochem., 243, 527-536.
370. Gray, N. S.,Wodicka, L.,Thunnissen, A.W. H., Norman,T. C., Kwon, S., Espinoza, F. H., Morgan, D. O., Barnes, G., LeClerc, S., Meijer, L. (1998). Exploiting chemical libraries, structure and genomics in the search for kinase inhibitors. Science, 281, 533-538.
371. Senderowicz,A. M. (2003). Novel small molecule cyclin-dependent kinases modulators in human clinical trials. Cancer Biol. Ther., 2, S84-95.
372. Goekjian, P. G., Jirousek, M. R. (2001). Protein kinase C inhibitors as novel anticancer drugs. Exp. Opin. Invest. Drugs, 10, 2117-2140.
373. Sorbera, L. A., Silvestre, J., Rabasseda, X., Castaner, J. (2000). LY-333531 mesylate hydrate: Symptomatic antidiabetic; protein kinase C inhibitor. Drugs Future, 25, 1017-1026.
374. Way, K. J., Chou, E., King, G. L. (2000). Identification of PKC-isoform-specific biological actions using pharmacological approaches. Trends Pharmacol. Sci., 21, 181-187.
375. Propper, D. J., McDonald, A. C., Man, A., Thavasu, P., Balkwill, F., Braybrooke, J. P., Caponigro, F., Graf, P., Dutreix, C., Blackie, R., Kaye, S. B., Ganesan, T. S., Talbot,D. C., Harris, A. L.,Twelves, C. (2001). Phase I and pharmacokinetic study of PKC412 an inhibitor of protein kinase C. J. Clin. Oncol., 19, 1485-1492.
376. Fuse, E.,Tanii, K., Kurata, N., Kobayashi, H., Shimada,Y.,Tamura,T.,Tanigawara, Y., Lush, R. D., Headlee, D., Figg, W. D., Arbuck, S. G., Senderowicz, A. M., Sauseville, E. A., Akinaga, S., Kuwabara, T., Kobayashi, S. (1998). Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein. Cancer Res., 58, 3248-3255.
377. Fuse, E., Tanii, K., Takai, K., Asanome, K., Kurata, N., Kobayashi, H., Kuwabara, T., Kobayashi, S., Sugiyama,Y. (1999). Altered pharmacokinetics of a novel anticancer drug, UCN-01, caused by specific high affinity binding to alpha1-acid glycoprotein in humans. Cancer Res., 58, 1054-1060.
378. Schaufelberger, D. E., Koleck, M. P., Beutler, J. A.,Vatakis, A. M., Atvardo, A. B., Andrews, L. V., Muschick, G. M., Forenza, S. (1991). The large scale isolation of bryostatin 1 from Bugula nerutina following current good manufacturing practices. J. Nat. Prod., 54, 1265-1270.
379. Smith, J. B., Smith, L., Pettit, G. R. (1985). Bryostatins: Potent, new mitogens that mimic phorbol ester tumour promoters. Biochem. Biophys. Res. Commun., 132, 939-945.
380. Szallasi, Z., Smith, C. B., Pettit, G. R., Blumberg, P. M. (1994). Differential regulation of protein kinase C isozymes by bryostatin 1 and phorbol 12-myristate 13-acetate in NIH 3t3. broblasts. J. Biol. Chem., 269, 2118-2124.
381. Hocevar, B. A., Fields, A. P. (1991). Selective translocation of bII protein kinase C to the nucleus of human promyelocytic (HL-60) leukemia cells. J. Cell. Biol., 266, 28-33.
382. Neumunaitis, J., Holmlund, J. T., Kraynak, M., Richards, D., Bruce, J., Ognoskie, N., Kwoh, T. J., Greary, R., Dorr, A., Von Hoff, D., Eckhardt, S. G. (1999). Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase Ca, in patients with advanced cancer. J. Clin. Oncol., 17, 3586-3595.
383. Breitenlechner, C., Gassel, M., Hidaka, H., Kinzel, V., Huber, R., Engh, R. A., Bossemeyer, D. (2003). Protein kinase A in complex with Rho-kinase inhibitors Y-27632, Fasudil, and H-1152P: Structural basis of selectivity. Struct. (Cambr.), 11, 1595-1607.
384. Walker, E. H., Pacold, M. E., Perisic, O., Stephens, L., Hawkins, P. T., Wymann, M. P.,Williams,R. L. (2000). Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol. Cell., 6, 909-919.
385. Lakkakorpi, P. T.,Wesolowski, G., Zimolo, Z., Rodan, G. A., Rodan, S. B. (1997). Phosphatidylinositol 3-kinase association with the osteoclast cytoskeleton, and its involvement in osteoclast attachment and spreading. Exp. Cell Res., 237, 296-306.
386. Hunag, S., Houghton, P. J. (2002). Inhibitors of mammalian target of rapamycin as novel antitumor agents: From bench to clinic. Curr. Opin. Invest. Drugs, 3, 295-304.
387. Podsypanina, K., Lee, R. T., Politis, C., Hennessy, I., Crane, A., Puc. J., Neshat, M., Wang, H., Yang, L., Gibbons, J., Frost, P., Dreisbach, V., Blenis, J., Gaciong, Z., Fisher, P., Sawyers, C., Hedrick-Ellenson, L., Parsons, R. (2001). An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/-mice. Proc. Natl. Acad. Sci. USA, 98, 10314-10319.